Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Language
Publication year range
1.
Int. braz. j. urol ; 43(5): 880-886, Sept.-Oct. 2017. tab, graf
Article in English | LILACS | ID: biblio-892890

ABSTRACT

ABSTRACT Background: With a high rate of recurrence, urolithiasis is a chronic disease that impacts quality of life. The Patient Reported Outcomes Measurement Information System is an NIH validated questionnaire to assess patient quality of life. We evaluated the impact of urolithiasis on quality of life using the NIH-sponsored PROMIS-43 questionnaire. Materials and Methods: Patients reporting to the kidney stone clinic were interviewed to collect information on stone history and demographic information and were asked to complete the PROMIS-43 questionnaire. Quality of life scores were analyzed using gender and age matched groups for the general US population. Statistical comparisons were made based on demographic information and patient stone history. Statistical significance was P<0.05. Results: 103 patients completed the survey. 36% of respondents were male, the average age of the group was 52 years old, with 58% primary income earners, and 35% primary caregivers. 7% had never passed a stone or had a procedure while 17% passed 10 or more stones in their lifetime. Overall, pain and physical function were worse in patients with urolithiasis. Primary income earners had better quality of life while primary caregivers and those with other chronic medical conditions were worse. Patients on dietary and medical therapy had better quality of life scores. Conclusions: Urolithiasis patients subjectively have worse pain and physical function than the general population. The impact of pain on quality of life was greatest in those patients who had more stone episodes, underscoring the importance of preventive measures. Stone prevention measures improve quality of life.


Subject(s)
Humans , Male , Female , Adult , Aged , Quality of Life/psychology , Urolithiasis/psychology , Patient Reported Outcome Measures , Pain/etiology , Pain/psychology , Sleep Wake Disorders/etiology , Sleep Wake Disorders/psychology , Information Systems , Case-Control Studies , Chronic Disease , Surveys and Questionnaires , Depression/etiology , Depression/psychology , Urolithiasis/complications , Fatigue/etiology , Fatigue/psychology , Middle Aged
2.
Int Braz J Urol ; 43(5): 880-886, 2017.
Article in English | MEDLINE | ID: mdl-28792186

ABSTRACT

BACKGROUND: With a high rate of recurrence, urolithiasis is a chronic disease that impacts quality of life. The Patient Reported Outcomes Measurement Information System is an NIH validated questionnaire to assess patient quality of life. We evaluated the impact of urolithiasis on quality of life using the NIH-sponsored PROMIS-43 questionnaire. MATERIALS AND METHODS: Patients reporting to the kidney stone clinic were interviewed to collect information on stone history and demographic information and were asked to complete the PROMIS-43 questionnaire. Quality of life scores were analyzed using gender and age matched groups for the general US population. Statistical comparisons were made based on demographic information and patient stone history. Statistical significance was P<0.05. RESULTS: 103 patients completed the survey. 36% of respondents were male, the average age of the group was 52 years old, with 58% primary income earners, and 35% primary caregivers. 7% had never passed a stone or had a procedure while 17% passed 10 or more stones in their lifetime. Overall, pain and physical function were worse in patients with urolithiasis. Primary income earners had better quality of life while primary caregivers and those with other chronic medical conditions were worse. Patients on dietary and medical therapy had better quality of life scores. CONCLUSIONS: Urolithiasis patients subjectively have worse pain and physical function than the general population. The impact of pain on quality of life was greatest in those patients who had more stone episodes, underscoring the importance of preventive measures. Stone prevention measures improve quality of life.


Subject(s)
Patient Reported Outcome Measures , Quality of Life/psychology , Urolithiasis/psychology , Adult , Aged , Case-Control Studies , Chronic Disease , Depression/etiology , Depression/psychology , Fatigue/etiology , Fatigue/psychology , Female , Humans , Information Systems , Male , Middle Aged , Pain/etiology , Pain/psychology , Sleep Wake Disorders/etiology , Sleep Wake Disorders/psychology , Surveys and Questionnaires , Urolithiasis/complications
3.
J Affect Disord ; 194: 120-7, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26820761

ABSTRACT

OBJECTIVES: To estimate the risk of fatal and non-fatal myocardial infarction (MI) and stroke in patients with bipolar I disorder compared to people without bipolar I disorder. METHOD: Utilizing a records-linkage system spanning 30 years (1966-1996), a population-based cohort of 334 subjects with bipolar I disorder and 334 age and sex-matched referents from Olmsted County, Minnesota, U.S. was identified. Longitudinal follow-up continued until incident MI or stroke (confirmed by board-certified cardiologist/neurologist), death, or study end date (December 31, 2013). Cox proportional hazards models assessed the hazard ratio (HR) for MI or stroke, adjusting for potential confounders. RESULTS: There was an increased risk of fatal or non-fatal MI or stroke (as a composite outcome) in patients with bipolar I disorder [HR 1.54, 95% confidence interval (CI) 1.02, 2.33; p=0.04]. However, after adjusting for baseline cardiovascular risk factors (alcoholism, hypertension, diabetes, and smoking), the risk was no longer significantly increased (HR 1.19, 95% CI 0.76, 1.86; p=0.46). LIMITATIONS: Small sample size for the study design. Findings were not retained after adjustment for cardiovascular disease risk factors. Psychotropic medication use during the follow-up was not ascertained and was not included in the analyses. CONCLUSION: This study in a geographically defined region in the U.S. demonstrated a significant increased risk of MI or stroke in bipolar I disorder, which was no longer significant after adjustment for cardiovascular risk factors.


Subject(s)
Bipolar Disorder/epidemiology , Myocardial Infarction/epidemiology , Stroke/epidemiology , Adult , Case-Control Studies , Cohort Studies , Female , Humans , Male , Middle Aged , Proportional Hazards Models , Risk Assessment , Risk Factors , United States/epidemiology
4.
Stroke ; 44(2): 437-41, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23287780

ABSTRACT

BACKGROUND AND PURPOSE: The best management of patients with unruptured brain arteriovenous malformations (BAVM) is controversial. In this study, we analyzed the stroke rate and functional outcomes of patients having stereotactic radiosurgery (SRS) for unruptured BAVM using the same eligibility criteria and primary end points as the ARUBA trial. METHODS: Retrospective observational study of 174 ARUBA-eligible patients having SRS from 1990 to 2005. RESULTS: The median follow-up after SRS was 64 months. Fifteen patients (8.7%) had a hemorrhagic stroke at a median of 21 months after SRS. Six patients (3.5%) had a focal neurological deficit and 4 patients died (2.3%). The risk of stroke or death was 10.3% at 5 years and 11.5% at 10 years. Twelve additional patients (6.9%) had a focal neurological deficit from either radiation-related complications (n=7) or subsequent resection (n=5). The risk of patients' having clinical impairment (modified Rankin Score ≥ 2) was 8.4% at 5 years and 12.0% at 10 years. Increasing BAVM volume was associated with both stroke or death (hazard ratio=1.06; 95% confidence interval, 1.0-1.11; P=0.04) and clinical impairment (hazard ratio=1.06; 95% confidence interval, 1.01-1.09; P=0.01). The 10-year risk of stroke or death and clinical impairment for patients with BAVM ≤ 5.6 cm(3) was 5% and 4%, respectively. CONCLUSIONS: The observed risk of stroke or death after SRS was approximately 2% per year for the first 5 years after SRS, declining to 0.2% annually for years 6 to 10. Patients with small volume BAVM may benefit from SRS compared with the natural history of unruptured BAVM over the planned follow-up interval of the ARUBA trial (5-10 years).


Subject(s)
Intracranial Arteriovenous Malformations/epidemiology , Intracranial Arteriovenous Malformations/surgery , Radiosurgery/adverse effects , Stroke/epidemiology , Adult , Female , Follow-Up Studies , Humans , Intracranial Arteriovenous Malformations/mortality , Male , Middle Aged , Prospective Studies , Randomized Controlled Trials as Topic , Retrospective Studies , Risk Factors , Stroke/diagnosis , Stroke/mortality , Survival Rate/trends , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL